FDA Accepts NDA for Insomnia Med Lemborexant, Target Date Set for Dec. 27

Eisai and its US partner Imbrium Therapeutics said on March 12 that the US FDA has accepted a new drug application for their insomnia treatment lemborexant, with the target action date under the Prescription Drug User Fee Act (PDUFA) set...read more